Erlotinib Hydrochloride Tablets.

Effects and efficacy: Erlotinib is an anti-tumor drug mainly used for non-small cell cancer. Erlotinib is used as a single agent for the first-line treatment, maintenance treatment or second-line or higher treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitive mutations in the epidermal growth factor receptor (EGFR) gene after at least one chemotherapy progression. It is used alone for the maintenance treatment of locally advanced or metastatic NSCLC with stable disease after 4 cycles of first-line chemotherapy based on platinum drugs. The results of two multicenter, randomized, placebo-controlled Phase III trials showed that erlotinib combined with platinum-containing chemotherapy (carboplatin + paclitaxel; or gemcitabine + cisplatin) as a first-line treatment for patients with locally advanced or metastatic NSCLC did not increase clinical benefits compared to platinum-containing chemotherapy alone, so it is not recommended for first-line treatment in the above situation. Usage and Dosage: Single-agent for non-small cell lung cancer: The recommended dose is 150 mg per day, and the medication is continued until the disease progresses or intolerable toxic reactions occur. If the dose needs to be reduced, it should be reduced by 50 mg each time under the guidance of a doctor. Please follow the doctor’s advice for details. The same medicine produced by different manufacturers may have inconsistent instructions. If you find inconsistencies in the instructions before taking the medicine, please consult a doctor or pharmacist in time.
Drug contraindications:
Allergic to this product is prohibited. Use with caution during pregnancy and lactation.
Related dosage forms:
Tablets